Literature DB >> 9505887

Expression of a marker for colonic crypt base cells is correlated with poor prognosis in human colorectal cancer.

A A van der Wurff1, J ten Kate, P T Marx, E P van der Linden, C C Beek, F J Bovelander, J Dekker, W N Dinjens, M F von Meyenfeldt, J W Arends, F T Bosman.   

Abstract

BACKGROUND: There is a need for markers in colorectal cancer which will allow subclassification of stage groups into subgroups with high versus low risk of recurrent disease. AIMS: To develop monoclonal antibodies that recognise antigens or immature crypt base cells, on the assumption that in a neoplasm undifferentiated but not the terminally differentiated cells will be responsible for tumour progression.
METHODS: Colon crypt cells which were isolated from human colonic mucosa by EDTA/EGTA incubation were studied. By stepwise harvesting, crypt base cell enriched fractions were obtained, and after incubation with antibodies against dominant antigens, used as immunogens.
RESULTS: Of one crypt base cell specific antibody (5E9), the reactive epitope appeared to be a non-terminal carbohydrate in the mucin O-glycans of the colon. The epitope did not seem to be colon specific, but was expressed in a variety of other tissues. In colorectal carcinomas, 5E9 immunoreactivity identified a subgroup of patients with a tendency for worse prognosis.
CONCLUSION: A mucin associated maturation epitope was identified in colonic crypt base cells, the expression of which in Dukes' stage B3 colorectal carcinoma may be associated with poor prognosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9505887      PMCID: PMC1726940          DOI: 10.1136/gut.42.1.63

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  32 in total

1.  Clonal origin of columnar, mucous, and endocrine cell lineages in human colorectal epithelium.

Authors:  S C Kirkland
Journal:  Cancer       Date:  1988-04-01       Impact factor: 6.860

2.  A method for the isolation and culture of human colonic crypts in collagen gels.

Authors:  R H Whitehead; A Brown; P S Bhathal
Journal:  In Vitro Cell Dev Biol       Date:  1987-06

3.  Expression of epithelial membrane antigen on malignant mesothelioma cells. An immunocytochemical and immunoelectron microscopic study.

Authors:  T H van der Kwast; M A Versnel; M Delahaye; A de Jong; P E Zondervan; H Hoogsteden
Journal:  Acta Cytol       Date:  1988 Mar-Apr       Impact factor: 2.319

Review 4.  Heterogeneity of human colon carcinoma.

Authors:  M G Brattain; A E Levine; S Chakrabarty; L C Yeoman; J K Willson; B Long
Journal:  Cancer Metastasis Rev       Date:  1984       Impact factor: 9.264

5.  Demonstration of somatic mutation and colonic crypt clonality by X-linked enzyme histochemistry.

Authors:  D F Griffiths; S J Davies; D Williams; G T Williams; E D Williams
Journal:  Nature       Date:  1988-06-02       Impact factor: 49.962

6.  The occurrence and clinicopathological significance of serotonin immunoreactive cells in large bowel carcinoma.

Authors:  J W Arends; T Wiggers; K Verstijnen; F T Bosman
Journal:  J Pathol       Date:  1986-06       Impact factor: 7.996

7.  Undifferentiated carcinoma of the colon containing exocrine, neuroendocrine and squamous cells.

Authors:  I Damjanov; P S Amenta; F T Bosman
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1983

8.  Regulation of vitamin D receptor abundance and responsiveness during differentiation of HT-29 human colon cancer cells.

Authors:  X Zhao; D Feldman
Journal:  Endocrinology       Date:  1993-04       Impact factor: 4.736

9.  No-touch isolation technique in colon cancer: a controlled prospective trial.

Authors:  T Wiggers; J Jeekel; J W Arends; A P Brinkhorst; H M Kluck; C I Luyk; J D Munting; J A Povel; A P Rutten; A Volovics
Journal:  Br J Surg       Date:  1988-05       Impact factor: 6.939

10.  Heterogeneous expression of two oncodevelopmental antigens, CEA and SSEA-1, in colorectal cancer.

Authors:  S H Itzkowitz; Z R Shi; Y S Kim
Journal:  Histochem J       Date:  1986-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.